6/12/2025
BioNTech to Acquire CureVac in Strategic All-Stock Deal to Accelerate Cancer Immunotherapy Innovation
In a major step forward for the future of mRNA-based medicine, BioNTech SE has announced it will acquire fellow German biotech firm CureVac N.V. in an all-stock deal valued at approximately $1.25 billion. The transaction is set to bolster BioNTech’s capabilities in cancer immunotherapy and mRNA research, positioning the company for deeper innovation and broader commercialization in oncology.
0
3 min read